AL-001

DRUG2 trials

Sponsors

Beijing Anlong Biopharmaceutical Co., Ltd.

Conditions

Wet Age-related Macular Degeneration (wAMD)

Phase 1

Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD

Active, not recruitingNCT06707753

Beijing Anlong Biopharmaceutical Co., Ltd.Wet Age-related Macular Degeneration (wAMD)

Start: 2023-09-11End: 2025-08-31Target: 21Updated: 2025-03-19

Phase 2

Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD

Not yet recruitingNCT06839339

Beijing Anlong Biopharmaceutical Co., Ltd.Wet Age-related Macular Degeneration (wAMD)

Start: 2025-02-18End: 2027-01-30Target: 40Updated: 2025-02-21